Guide

Mounjaro for Weight Loss: The Same Molecule at Three Times the Price

Mounjaro and Zepbound are both tirzepatide. The difference is the approved indication — diabetes against weight management. There is no manufacturer self-pay programme fo

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-07-26Updated 2026-07-26Sources captured 2026-07-26Medically reviewed not yet — why

Direct answer

Mounjaro and Zepbound are both tirzepatide. The difference is the approved indication — diabetes against weight management. There is no manufacturer self-pay programme for Mounjaro at weight-loss doses, so telehealth providers list it near retail at $1,100 to $1,899 a month. If you are paying cash, Zepbound is the same molecule at $299 to $449.

Answer last reviewed: 2026-07-26

Same molecule, different label

Mounjaro against Zepbound
	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Approved for	Type 2 diabetes	Chronic weight management; also obstructive sleep apnoea in adults with obesity
Manufacturer self-pay programme	None at weight-loss doses	LillyDirect Self Pay Journey Program
Typical cash price	$1,100 to $1,899 a month at telehealth providers	$299 to $449 through LillyDirect
Insurance coverage	More commonly covered, requires a type 2 diabetes diagnosis	Excluded from Medicare Part D and most state Medicaid; commonest through employer plans

Zepbound figures captured from Lilly's own pages on 27 July 2026. Mounjaro figures are provider-reported and we have not captured them.

Why the price gap exists

Eli Lilly priced and marketed the two as separate products. It launched a direct self-pay programme for Zepbound and did not do the same for Mounjaro at weight-loss doses. That is a commercial decision rather than a clinical one, and it is the whole explanation for the gap.

When Mounjaro is the right purchase

One situation: your insurance covers Mounjaro and your copay is lower than your alternatives. That typically requires a type 2 diabetes diagnosis, because that is the approved indication.

Coverage for Mounjaro is more common than for Zepbound, because diabetes coverage is refused far less often than weight-management coverage for the same molecules. If you have type 2 diabetes and a plan that covers it, this is likely your cheapest route by a wide margin.

Outside that, paying cash for Mounjaro to lose weight means paying roughly three times as much for the same molecule.

Off-label prescribing is not the same as being covered

Mounjaro is prescribed off-label for weight loss. Off-label prescribing is lawful and routine. What it does not do is make your plan pay: a plan that covers Mounjaro for diabetes will not usually cover it for weight management, and prior authorisation will typically require the diagnosis codes.

Describing your situation in particular terms to obtain approval is both bad advice and, in some framings, fraud. What our prior authorization guide covers is which documentation the published criteria actually require.

What the trials say, and which they were

Tirzepatide's diabetes evidence is the SURPASS programme, which enrolled over 10,000 patients. At 40 weeks, 5 mg weekly reduced HbA1c by roughly 1.87 to 2.07 percentage points against placebo, with 10 and 15 mg achieving 2.0 to 2.5 points. Weight loss at that point ranged from 7 to 12 kg by dose.

The weight-management evidence is SURMOUNT. SURMOUNT-1 reported up to 22.5% mean body-weight reduction at 15 mg over 72 weeks on the efficacy estimand. SURMOUNT-5, the head-to-head against semaglutide 2.4 mg, reported 20.2% against 13.7%.

Same molecule, so the pharmacology is the same. The trials differ because the populations and endpoints do.

The routes worth checking first

Coverage for either product. Ask about the indication, not the drug name.
Zepbound self-pay at $299 to $449 if you have no coverage and want brand.
The Medicare GLP-1 Bridge at $50 a month for eligible enrollees, to 31 December 2027.
Compounded tirzepatide, a different regulatory category with its own questions — see what is actually in it.

Cash-pay Mounjaro for weight loss does not appear on that list, and we cannot construct a scenario where it should.

Medical noteDose decisions belong with the clinician who prescribed your medication. This page describes what product labels and manufacturer pages state.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Questions readers actually ask

How much does Mounjaro cost for weight loss?

Telehealth providers list it near retail at $1,100 to $1,899 a month, because there is no manufacturer self-pay programme for Mounjaro at weight-loss doses.

Is Mounjaro the same as Zepbound?

Both are tirzepatide. The difference is the approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnoea.

Should I buy Mounjaro instead of Zepbound?

Only if your insurance covers Mounjaro and your copay is lower, which typically requires a type 2 diabetes diagnosis. Paying cash means roughly three times the price for the same molecule.

Why is Mounjaro more expensive?

Lilly launched a direct self-pay programme for Zepbound and not for Mounjaro at weight-loss doses. It is a commercial decision rather than a clinical one.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Mounjaro for Weight Loss: The Same Molecule at Three Times the Price.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/mounjaro-cost-weight-loss/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Report an error

Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.